Blood coagulants

Tender description

NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points. NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points. NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points. NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points. NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.